Anti-Obesity Medication
[Extra! Extra!] ADM Releases Insights from Anti-Obesity Medication Survey
The adoption of anti-obesity medications (AOMs) such as GLP-1 receptor agonists continues to accelerate globally with spending set to reach nearly $200 billon by 2029, according to the IQVIA Institute for Human Data Science. Illinois-based ADM’s latest proprietary consumer survey examines the latest AOM landscape, showing how both current and transitioning users are reshaping expectations ...
Don't Miss Out!
Industry Professionals
Stay Informed!
Stay informed about the latest health, nutrition, and wellness developments by signing up for a FREE subscription to Nutrition Industry Executive magazine and digital newsletter.
Once subscribed, you will receive industry insights, product trends, and important news directly to your doorstep and inbox.


